Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN50011192
ISRCTN50011192
Completed
Not Applicable

A dose response study of the effects of increased fruit and vegetables intake on vascular functio

Food Standards Agency (UK)0 sites48 target enrollmentSeptember 9, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Food Standards Agency (UK)
Enrollment
48
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 9, 2005
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Food Standards Agency (UK)

Eligibility Criteria

Inclusion Criteria

  • •Subjects will be male or female, non\-smoking and aged between 22\-65 years. A principal aim is to identify and recruit subjects with moderate elevation of Blood Pressure (BP). Eligible subjects will have diastolic more than 80 mmHg and less than 100 mmHg and a systolic BP of less than 160 mmHg.

Exclusion Criteria

  • •1\. Current smokers
  • •2\. A reported history of myocardial infarction or cancer
  • •3\. Diabetes mellitus (fasting plasma glucose more than 7 mmol/l)
  • •4\. Recent use of oral hypolipidaemic therapy, systemic corticosteroids, androgens, phenytoin, erythromycin or thyroid hormones
  • •5\. Current use of antihypertensive medication
  • •6\. Those receiving drugs for regulating haemostasis but excluding aspirin or who have been exposed to any investigational agent within 30 days of the study
  • •7\. Chronic coronary, renal or bowel disease or history of cholestatic liver disease or pancreatitis
  • •8\. Presence of gastrointestinal disorder or use of a drug, which is likely to alter gastrointestinal motility or nutrient absorption
  • •9\. History of substance abuse or alcoholism
  • •10\. Currently pregnant, planning pregnancy, or having had a baby in the last 12 months

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A study to evaluate the dose-response effect of tolvaptan 7.5mg or 15mg in HF patients who undergo cartdiac angiographyHeart Failure
JPRN-UMIN000009924Showa University Northern Hospital100
Recruiting
Not Applicable
A study for the difference in effects of high-dose prednisolone therapy for autoimmune disease patientsrheumatic disease like dermatomyositis, polymyositis, systemic lupus erythematosus, vasculitides, adult Still&#39s disease and so on.
JPRN-UMIN000007673Graduate School of Medicine Kyoto University Rheumatology and Clinical Immunology100
Active, not recruiting
Phase 1
Investigation of dose response relationships when using low dose naltrexone (LDN) for the treatment of fibromyalgiaFibromyalgiaMedDRA version: 20.0Level: LLTClassification code 10016631Term: Fibromyalgia syndromeSystem Organ Class: 100000004859Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2016-002081-31-DKAnæstesiologisk-intensiv afd V, Odense Universitets Hospital38
Active, not recruiting
Not Applicable
An evaluation of the dose-response relationship of Cizolirtine citrate 300 mg, twice daily, and 400 mg, twice daily, versus placebo in subjects with urge urinary incontinence.A 12-week, randomised, double-blind, placebo-controlled, multicentre study, parallel-group, Phase III clinical study with a 12 months safety follow-up period.rge Urinary Incontinence
EUCTR2004-001119-69-ESaboratorios Dr. Esteve, SA450
Active, not recruiting
Phase 1
An evaluation of the dose-response relationship of Cizolirtine citrate 300 mg, twice daily, and 400 mg, twice daily, versus placebo in subjects with urge urinary incontinence.A 12-week, randomised, double-blind, placebo-controlled, multicentre study, parallel-group, Phase III clinical study with a 12 months safety follow-up period.rge Urinary Incontinence
EUCTR2004-001119-69-CZaboratorios Dr. Esteve, SA450